Pikkelysömör: vizsgálatok itt: Spanyolország

In Spanyolország 18 Also abroad 274

18 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.

4. fázisTaking people
Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)
Where
Barcelona, Bilbao, Ciudad Real, Córdoba, Elche, Las Palmas De Gran Canaria, Madrid, Murcia, Orihuela, Palma, San Cristóbal de La Laguna, Santander, Sant Joan d'Alacant, Torrelavega, Vitoria, Hospital laredo
Életkor
50 év and over
People
1944
Run by
Instituto de Investigación Marqués de Valdecilla
See details and how to joinNCT07611747 · EU 2025-521086-28-00
4. fázisTaking people
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
Where
Bilbao, Madrid, Sabadell, Santiago de Compostela, Sevilla, Valencia
People
339 worldwide
Run by
Novartis Pharma AG
See details and how to joinNCT04638647 · EU 2023-504417-67-00
No phaseTaking people
A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
Where
Badalona, Barcelona, Madrid, Málaga, San Cristóbal de La Laguna, Valencia, Zaragoza
Életkor
18 év to 100 év
People
150
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07683065
3. fázisTaking people
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Where
Santiago de Compostela, Valencia
Életkor
3 év to 64 év
People
196 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00
3. fázisTaking people
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Where
Badalona, Barcelona, Las Palmas De Gran Canaria, Madrid, Malaga, Salamanca, Sevilla
Életkor
40 év and over
People
3040 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07116967 · EU 2023-503766-24-00
3. fázisTaking people
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Where
Barcelona, Madrid, Santiago de Compostela- A Coruna
Életkor
12 év to 17 év
People
366 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06979453 · EU 2023-506296-97-00
3. fázisTaking people
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
Where
Alicante, Barakaldo, Esplugues De Llobregat, Las Palmas de Gran Canaria, Madrid
Életkor
4 év to 18 év
People
153 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT04772079 · EU 2022-502519-13-00
2. fázisTaking people
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Where
Badalona, Barcelona, Madrid
Életkor
18 év and over
People
240 worldwide
Run by
Oruka Therapeutics, Inc.
See details and how to joinNCT07449702 · EU 2026-526898-42-00
3. fázisTaking people
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Where
Badajoz, Málaga, Sabadell, Santiago de Compostela, Sevilla, Valencia
Életkor
18 év and over
People
1088 worldwide
Run by
Takeda
See details and how to joinNCT06671483 · EU 2024-513111-27-00
No phaseTaking people
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Where
Cartagena, El Palmar, León, Málaga, Murcia, Pontevedra, Toledo
Életkor
18 év and over
People
700 worldwide
Run by
AbbVie
See details and how to joinNCT07039110
No phaseNot yet taking people in Spanyolország
Ceramol PSOR Cream as an Adjuvant Treatment in Patients With Mild-to-Moderate Psoriasis Treated With Narrowband UVB Phototherapy (CERAMOL PSOR CREMA)
Where
Madrid
Életkor
18 év and over
People
128
Run by
Unifarco SpA
See details and how to joinNCT07849101
1. fázisTaking people
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
Where
Barcelona
Életkor
18 év and over
People
20 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT06888193 · EU 2024-518689-29-00
3. fázisTaking people
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
Where
Alicante, Barcelona, Madrid, Santiago de Compostela
Életkor
4 év to 17 év
People
110 worldwide
Run by
Takeda
See details and how to joinNCT07250802 · EU 2025-522567-15-00
3. fázisTaking people
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Where
Alcobendas, Badajoz, Madrid, Málaga, Sabadell, San Cristóbal de La Laguna, Santander, Santiago de Compostela, Sevilla, Valencia, Vitoria
Életkor
18 év and over
People
1182 worldwide
Run by
Takeda
See details and how to joinNCT07286058 · EU 2025-522586-30-00
3. fázisTaking people
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Where
Esplugues De Llobregat, Valencia
Életkor
5 év to 17 év
People
40 worldwide
Run by
AbbVie
See details and how to joinNCT06100744 · EU 2023-506026-36-00
3. fázisTaking people
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Where
Alicante, Barakaldo, Barcelona, Granada, L'hospitalet De Llobregat, Madrid, Valencia
Életkor
18 év and over
People
320 worldwide
Run by
Janssen - Cilag International
See details and how to join2023-505121-14-00 · EU 2023-505121-14-00
3. fázisTaking people
A Phase 3 Mechanistic Longitudinal Study to Evaluate the Impact of EARLY Risankizumab Treatment on TRM Cell Levels in Moderate-to-Severe Psoriasis
Where
Madrid
Életkor
18 év and over
People
30
Run by
Icr Medical S.L.
See details and how to join2025-521424-30-00 · EU 2025-521424-30-00
No phaseTaking people
An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
Where
Granada, Huelva, Lorca, Madrid, Málaga, Murcia, Seville, Vigo
Életkor
18 év to 75 év
People
1200 worldwide
Run by
AbbVie
See details and how to joinNCT06764693